March 11, 2026 | FDA Announcements, Adverse Event Reporting
On March 11, 2026, the FDA officially launched the Adverse Event Monitoring System (AEMS), a unified platform designed to consolidate the agency's previously fragmented adverse event databases into a single, publicly accessible system. The announcement marks a significant shift in how adverse event data is collected, displayed, and made available across all FDA-regulated product categories — from drugs and vaccines to cosmetics, animal health products, and dietary supplements.
For companies already managing adverse event reporting programs, the practical impact of this change is worth understanding. The systems you may be familiar with — FAERS, VAERS, MAUDE, and others — are being replaced or absorbed. Reporting obligations themselves have not changed, but the infrastructure around those reports is being significantly modernized.
| Key Developments |
|---|
| What FDA announced: The FDA launched AEMS, a unified adverse event monitoring platform consolidating multiple legacy databases into a single system. |
| Databases currently included: FAERS (drugs, biologics, cosmetics, color additives), VAERS (vaccines), and AERS (animal drugs and foods) |
| Databases coming in May 2026: MAUDE (medical devices), HFCS (human foods and dietary supplements), CTPAE (tobacco products) |
| Why it matters: Companies that submit adverse event reports and conduct post-market surveillance will interact with a new, unified public dashboard for cross-product data. |
| Projected cost savings: Approximately $120 million over five years, replacing systems that collectively cost $37 million per year to operate. |
| Data limitations: Reports in AEMS do not establish causation and have not been independently verified. |
Background: Why the FDA Consolidated Its Adverse Event Systems
For decades, the FDA operated a collection of separate adverse event databases, each tied to a specific product category. These included FAERS for drugs and biologics, VAERS for vaccines, MAUDE for medical devices, and AERS for animal products, among others. While each system served its intended purpose, the fragmented architecture created operational challenges for both the agency and the companies submitting reports.
According to the FDA's press release, these systems collectively cost approximately $37 million per year to operate and presented a poor user interface that made data searches difficult.
The agency also noted that its previous infrastructure resulted in adverse event reports being published quarterly rather than in real time, limiting public access and increasing FOIA requests for unreleased data. AEMS addresses both issues by moving to real-time publication of adverse event reports, within the constraints of protecting individually identifiable patient and consumer information.
What AEMS Is and How It Works
AEMS is a revamped and renamed version of the FAERS system, expanded to incorporate data from several other legacy databases. The public-facing component is an interactive dashboard that allows stakeholders, researchers, and the public to query adverse event data across product categories in a more streamlined interface.
According to the FDA, the goals of AEMS include:
- Improve the quality and consistency of adverse event data by standardizing reporting protocols.
- Reduce the administrative burden of adverse event reporting for both FDA staff and external stakeholders.
- Support more effective post-market surveillance through modern case processing tools, AI-assisted redaction and digitization, improved data analytics, and cross-product surveillance.
- Act as a single dashboard for consumer complaints and regulatory misconduct reports across all FDA product centers, not just adverse event submissions.
As of launch, the AEMS public dashboard includes data from FAERS (drugs, biologics, cosmetics, and color additives), VAERS (vaccines, co-managed with the CDC), and AERS (animal drugs and animal foods). Remaining legacy systems — MAUDE, HFCS, and CTPAE — are expected to transition into AEMS by the end of May 2026.
Legacy Systems: What's Changing and When
| Legacy System | Product Categories Covered | Status |
|---|---|---|
| FAERS | Drugs, biologics, cosmetics, color additives | Now integrated into AEMS |
| VAERS | Vaccines (co-managed with CDC) | Data displayed in AEMS; VAERS remains online |
| AERS | Animal drugs and animal foods | Now integrated into AEMS |
| MAUDE | Medical devices | *Transitioning to AEMS by May 2026 |
| HFCS | Human foods, dietary supplements | *Transitioning to AEMS by May 2026 |
| CTPAE | Tobacco and ENDS products | *Transitioning to AEMS by May 2026 |
*Timelines reflect the FDA's stated plans as of the March 11, 2026 press release. Monitor FDA.gov for updates.
One important note regarding VAERS: because it is co-managed by the FDA and the Centers for Disease Control and Prevention (CDC), the VAERS website and its existing infrastructure remain online. VAERS webpages have not been updated to reflect the AEMS transition, and the CDC's role in vaccine safety monitoring continues unchanged.
What AEMS Means for Adverse Event Reporting
For companies across regulated industries, the launch of AEMS does not change the underlying reporting obligations. If your products are subject to adverse event reporting requirements — whether under DSHEA, MoCRA, medical device MDR requirements, or another framework — those requirements remain in effect as written in the applicable regulations.
What changes is the infrastructure on the receiving end. As the FDA migrates historical data and integrates remaining systems, companies should expect the following:
More Accessible Public Data
Real-time publication of adverse event data is not entirely new — the FAERS public dashboard moved to daily updates in August 2025 for drugs, biologics, and cosmetics. The FDA has been clear, however, that the primary driver behind real-time publication is to strengthen the agency's own postmarket surveillance and signal detection capabilities. By eliminating the lag of quarterly data releases, FDA reviewers can identify and act on emerging safety signals more quickly.
For companies, it's worth keeping in mind that manufacturers subject to adverse event reporting requirements already have access to their own submitted data as it is collected — often before AEMS completes its ingestion cycle. What AEMS changes for industry is visibility into reports submitted by other parties involving your products, or patterns emerging across product categories that a single-category view would miss. For product categories that previously lacked a comparable public-facing tool — including animal health products, and eventually medical devices, dietary supplements, and human foods — AEMS does represent a meaningful expansion of what data is publicly queryable.
A Single Dashboard for Cross-Product Research
Previously, researchers and compliance teams querying adverse event data across multiple product categories had to navigate separate databases with different interfaces. AEMS consolidates this into a single platform, simplifying surveillance work for companies managing products across multiple regulated categories and potentially improving insight into confounding factors, such as other involved products.
Data Limitations Remain Important
The FDA's guidance on interpreting AEMS data is explicit and worth keeping in mind as more stakeholders interact with the system. Reports in AEMS are not verified and do not establish causation. A report appearing in AEMS does not mean the product caused the adverse event — the event may be related to underlying conditions, concurrent medications, or other factors. Rates of occurrence cannot be calculated from these reports, and the existence of a report is not an indicator of a product's overall safety profile.
FOIA Volume May Decrease
The FDA noted that real-time publication of adverse event reports is expected to reduce agency FOIA requests for unreleased data. This is a secondary effect, but it reflects the FDA's broader transparency goals with this initiative.
What Companies Should Consider Now
For companies with active adverse event reporting programs, the AEMS launch is primarily a systems and transparency change rather than a compliance event. That said, there are a few practical areas worth reviewing.
Familiarize Your Team with the AEMS Dashboard
AEMS is now the primary tool for accessing publicly available adverse event data. The FDA's public dashboard is live and searchable at fis.fda.gov. Understanding how to query and interpret the data — and its limitations — will be important as historical data migrates into the system over the coming months.
Confirm Your Reporting Channels Are Unaffected
The FDA has not yet announced any changes to legacy reporting channels as part of the AEMS transition. That said, companies should monitor FDA communications for any updates as legacy systems are migrated, and ensure they remain compliant with current reporting requirements in the meantime.
Consider How Real-Time Data Affects Signal Monitoring
The move to real-time publication changes the cadence of publicly available adverse event information. Programs previously operating on quarterly data refresh cycles may want to evaluate whether more frequent monitoring is warranted.
Watch for MAUDE, HFCS, and CTPAE Transitions
Medical device companies using MAUDE data, food and dietary supplement companies referencing HFCS, and tobacco products companies whose data goes to CTPAE should be aware that those systems are expected to transition to AEMS by May 2026. The FDA has indicated it will migrate historical data. Monitoring FDA.gov for updates on the migration timeline is advisable as that date approaches.
SafetyCall's Take: What AEMS Means for Safety Monitoring Programs
The launch of AEMS reflects a broader shift in how the FDA approaches post-market surveillance infrastructure. Real-time publication of adverse event data was cited by the FDA as a key mechanism for improving the agency's own ability to detect and act on safety signals — reducing the lag between when reports are submitted and when they become available for FDA reviewers to analyze.
In practice, the real-time benefit is more nuanced for companies already running structured safety monitoring programs. Drug and vaccine manufacturers, for example, are already notified by the FDA when third-party reports involving their products are submitted — meaning AEMS does not materially change their access to that data. Where AEMS may offer more incremental value is cross-category visibility: a safety team can now query patterns across product categories in a single interface, which could surface multi-product incidents that would previously have required navigating separate systems.
For companies that have not previously monitored publicly available adverse event data, AEMS simplifies the starting point — one interface rather than several disconnected systems to learn and track separately.
A note of caution is warranted here, however. More accessible data cuts both ways. The same single-dashboard experience that benefits a compliance team also lowers the barrier for plaintiff attorneys, competitors, and independent researchers to mine adverse event patterns across product categories. Because AEMS reports — specifically the MedWatch 3500A form — contain limited information (no narratives, restricted outcome details), users without clinical or regulatory context may draw incomplete or misleading conclusions from what appears to be a robust dataset. Companies should be prepared for increased scrutiny driven by AEMS-sourced searches and have a clear interpretive framework ready — both for internal decision-making and for responding to external inquiries that may be based on incomplete data.
On the submission side, the FDA has not announced any changes to legacy reporting channels as part of the AEMS transition. Companies should monitor FDA communications for updates as remaining legacy systems migrate and ensure reporting workflows remain compliant with current requirements in the meantime.
Frequently Asked Questions About AEMS
What is AEMS?
AEMS stands for Adverse Event Monitoring System. It is the FDA's new unified platform for collecting and displaying adverse event reports across all FDA-regulated product categories, including drugs, biologics, vaccines, cosmetics, animal health products, dietary supplements, and medical devices. It replaces a collection of separate legacy databases that previously operated independently.
Does the launch of AEMS change adverse event reporting requirements?
No. The underlying regulatory requirements for adverse event reporting have not changed. Companies subject to reporting obligations under DSHEA, MoCRA, medical device MDR regulations, or other frameworks should continue to follow those requirements as written. AEMS is a change to the FDA's data infrastructure and public-facing tools, not to the regulations themselves.
Which legacy databases has AEMS already replaced?
As of the March 2026 launch, AEMS incorporates data from FAERS (drugs, biologics, cosmetics, and color additives), VAERS (vaccines), and AERS (animal drugs and animal foods). MAUDE (medical devices), HFCS (human foods and dietary supplements), and CTPAE (tobacco products) are expected to transition to AEMS by May 2026.
Will VAERS still be available?
Yes. Because VAERS is co-managed by the FDA and the CDC, it remains online. The FDA is displaying VAERS data within AEMS, but the VAERS website and the CDC's ongoing role in vaccine safety surveillance are not affected by this transition.
What are the limitations of AEMS data?
The FDA is explicit that adverse event reports in AEMS do not establish causation, have not been independently verified, and cannot be used to calculate rates of occurrence. A report in AEMS reflects the reporter's observations, not a confirmed determination that the product caused the event, and events may contain incomplete information.
How can my team access AEMS data?
The FDA AEMS Public Dashboard is available at fis.fda.gov. The agency has also indicated it will roll out enhanced APIs and data analytics tools to support more sophisticated querying as the system matures.
How does AEMS affect post-market surveillance programs?
AEMS consolidates previously fragmented public adverse event data into a single interface, which may streamline how companies access and query that information. However, the system is primarily designed to enhance the FDA's own signal detection capabilities — and for most companies with structured surveillance programs, the underlying data is not new. Clinical evaluation and regulatory reporting obligations remain unchanged and require appropriate expertise regardless of what AEMS contains.
About This Update
This article summarizes the FDA's March 11, 2026 announcement and press release regarding the AEMS launch. For the complete press release, visit FDA.gov. For the AEMS public dashboard and data limitations guidance, visit fda.gov/safety/fda-adverse-event-monitoring-system-aems.
We work with companies across 12 industries to build and manage adverse event reporting programs tailored to their specific product categories and regulatory requirements. If you have questions about how AEMS affects your post-market surveillance program or your reporting processes, contact us to discuss your needs.
